Floatz logo

Sacituzumab Tirumotecan

Triple-Negative Breast Carcinoma

Yale Universityantibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

427 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Sacituzumab Tirumotecan is also rated in:

non-small cell lung carcinomaActive
B
Indicative · Phase 3
63 / 100
View asset →
small cell lung carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →